INDGN
Indegene Limited (INDGN) Stock Analysis
Indegene Limited provides digital-first commercialization solutions to global pharmaceutical and life-sciences clients. It offers medical affairs, analytics, and technology-enabled engagement for drug launches. The company is an India-rooted listed health-tech services firm with offshore delivery.
Healthcare › Health Information Services
₹598.30
+3.14% 1W | +10.00% 52W
Market Cap
14.4k CR
P/E Ratio
36
52W High
₹627
52W Low
₹414
Div. Yield
0.38%
Beta
0.8
50 DMA
₹583.8
200 DMA
₹517.4
Profit Margin
10.5%
Inst. Own.
26.9%
⚡ APPROACHING SUPPORT
⚡ APPROACHING SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 608 | 636 | 673 | 673 | 676 | 687 | 720 | 756 | 761 | 804 | 942 | 1,003 | 1,063 |
| Expenses | 511 | 515 | 524 | 534 | 548 | 561 | 589 | 608 | 606 | 664 | 783 | 840 | 889 |
| Operating Profit | 97 | 121 | 149 | 139 | 129 | 126 | 132 | 148 | 155 | 141 | 160 | 164 | 174 |
| OPM % | 16% | 19% | 22% | 21% | 19% | 18% | 18% | 20% | 20% | 17% | 17% | 16% | 16% |
| Other Income | 28 | 12 | 13 | 26 | 22 | 21 | 38 | 26 | 22 | 20 | 19 | -10 | 29 |
| Interest | 13 | 12 | 12 | 12 | 12 | 4 | 3 | 3 | 4 | 4 | 5 | 7 | 6 |
| Depreciation | 20 | 20 | 18 | 18 | 20 | 19 | 20 | 21 | 22 | 23 | 40 | 42 | 44 |
| Profit before tax | 92 | 101 | 132 | 134 | 120 | 124 | 146 | 149 | 152 | 133 | 135 | 105 | 153 |
| Tax % | 26% | 25% | 25% | 29% | 27% | 26% | 25% | 21% | 23% | 23% | 24% | 24% | 24% |
| Net Profit | 68 | 75 | 99 | 95 | 88 | 92 | 110 | 118 | 116 | 102 | 103 | 80 | 116 |
| EPS in Rs | 3.08 | 3.38 | 4.45 | 4.26 | 3.67 | 3.83 | 4.58 | 4.90 | 4.85 | 4.25 | 4.28 | 3.31 | 4.82 |
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 553 | 643 | 966 | 1,665 | 2,306 | 2,590 | 2,839 | 3,510 | 3,813 |
| Expenses | 511 | 499 | 736 | 1,378 | 1,910 | 2,084 | 2,292 | 2,892 | 3,175 |
| Operating Profit | 42 | 144 | 230 | 287 | 396 | 505 | 548 | 619 | 638 |
| OPM % | 8% | 22% | 24% | 17% | 17% | 20% | 19% | 18% | 17% |
| Other Income | 7 | -102 | -3 | -21 | 58 | 79 | 94 | 52 | 59 |
| Interest | 6 | 9 | 7 | 6 | 31 | 49 | 22 | 19 | 22 |
| Depreciation | 17 | 19 | 26 | 33 | 60 | 76 | 80 | 126 | 149 |
| Profit before tax | 26 | 14 | 195 | 226 | 363 | 459 | 539 | 525 | 526 |
| Tax % | 45% | 191% | 23% | 28% | 27% | 27% | 25% | 24% | |
| Net Profit | 14 | -12 | 149 | 163 | 266 | 337 | 407 | 401 | 401 |
| EPS in Rs | 0.71 | -0.32 | 7.55 | 7.44 | 11.99 | 15.14 | 16.95 | 16.65 | 16.66 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 12% | 13% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 15.0% | 29.0% | – |
| Profit CAGR | 16.0% | 23.0% | – |
Shareholding Pattern
FIIs10.04%
DIIs7.20%
Public82.75%
FIIs11.30%
DIIs6.95%
Public81.74%
FIIs11.48%
DIIs8.06%
Public80.44%
FIIs10.27%
DIIs8.29%
Public81.43%
FIIs9.92%
DIIs8.74%
Public81.34%
FIIs5.24%
DIIs4.96%
Public89.80%
FIIs10.27%
DIIs8.29%
Public81.43%
FIIs9.92%
DIIs8.74%
Public81.34%
INDGN
Holdings Analysis
Key strengths & risk signals
65
Overall
62
Fundamental
69
Technical
Risks (2)
TOO MUCH PUBLIC HOLDING! 92.38% public ownership - higher volatility risk.
POSITIVE YEAR! Stock gained 7.6% in the last year.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (582.1) is above 200-day average (516.7) - positive signal.
STRONG! Trading at 85.9% of 52W range - near yearly highs.
STRONG POSITION! Current price (596.9) is above both moving averages.
Fundamental & Technical Analysis
69Overall
62Fundamental
76Technical
Fundamental Breakdown
Growth Quality
22/30
Revenue CAGR: 15.0% (GOOD, 11/15). Profit CAGR: 14.7% (GOOD, 11/15).
Profit Margin
5/10
DECENT EFFICIENCY! 10.5% profit margin - acceptable profitability.
PEG Valuation
7/10
OVERVALUED! PEG of 2.45 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.38% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.04 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 92.38% public ownership - higher volatility risk.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (583.8) is above 200-day average (517.4) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (598.3) is above both moving averages.
Trend Pattern
10/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
4/10
POSITIVE YEAR! Stock gained 10.0% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 14 up days, 15 down days. Avg volume on up days: 504,697 vs down days: 383,663. Ratio: 1.32x
RSI
3/5
NEUTRAL! RSI at 54.4 - balanced momentum.
52W Range
5/5
STRONG! Trading at 86.5% of 52W range - near yearly highs.
Momentum
5/5
STRONG MOMENTUM! Price has grown across all timeframes - up 3.1% (1 week), 4.4% (1 month), 17.1% (3 months). Momentum is accelerating.
Beta
4/5
BELOW MARKET! Beta of 0.80 - slightly less volatile than market.
INDGN
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-06 | Concall PDF | |
| Q4FY262026-05-06 | Concall PDF | |
| Q3FY262026-02-04 | Concall PDF | |
| Q2FY262025-11-03 | Concall PDF | |
| Q1FY262025-10-08 | Concall PDF |
Peer Comparison
Healthcare · Health Information Services · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INDGN | ₹598.30 | 36 | 10.5% | 15.0% | 14.7% | +10.0% | 69 | APPROACHING SUPPORT | -0.2% | +45.8% | +39.7% | +5.9% |
| SAGILITY | ₹45.30 | 21.4 | 13.0% | 19.5% | 86.1% | -0.5% | 77 | APPROACHING RESISTANCE | +45.9% | -15.9% | +27.6% | -3.0% |
| FABTECH | ₹130.30 | 10.6 | 11.7% | 28.3% | 20.8% | -26.4% | 65 | BREAKDOWN | -168.9% | -81.0% | +10.3% | -52.7% |
| TAKE | ₹12.60 | 32.3 | 15.2% | -34.1% | – | -41.5% | 38 | CONSOLIDATING DOWN | -283.3% | -75.0% | – | -43.9% |
| IKS | ₹1,731.40 | 38.7 | 22.8% | 45.8% | 33.2% | +13.9% | 79 | CONSOLIDATING UP | +27.9% | -6.0% | +20.7% | +4.2% |
| NATCOPHARM | ₹785.00 | 12.4 | 32.8% | 14.5% | 25.6% | -4.8% | 66 | APPROACHING SUPPORT | -57.0% | -22.9% | -44.7% | -0.5% |
| VIJAYA | ₹1,381.70 | 76 | 21.9% | 21.0% | 26.9% | +41.3% | 74 | BREAKDOWN | +37.6% | +10.9% | +22.8% | +5.3% |
| MARKSANS | ₹311.00 | 27.3 | 16.3% | 16.7% | 16.2% | +73.9% | 70 | BREAKDOWN | +169.6% | +6.1% | +35.6% | -1.8% |
Data from TradeAlone · Updated daily
INDGN News
Indegene Limited (indgn) Wins Frost & Sullivan’s 2026 Global Enabling Technology Leadership Recognition2026-10-22Indegene Limited (indgn): Indegene Digital Summit 2026 Signals Growing Influence in AI2026-10-06Indegene Limited (indgn): from Promise to Performance: Life Sciences Leaders Focus on Operationalizing AI2026-09-23Indegene Limited (INDGN) breaks out, moves up 5% intraday2026-08-03Indegene Limited (indgn) Q1 FY27: Revenue Up 39.7% Yoy, PAT Up 45.9% Qoq2026-07-30Indegene Limited (NSE: INDGN) climbs up 5% intraday, nears resistance2026-07-10Indegene Named Leader in Isg Provider Lens for Digital Services2026-05-04
